We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Momenta Pharmaceuticals Inc | NASDAQ:MNTA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.48 | 47.70 | 52.45 | 0 | 00:00:00 |
As filed with the Securities and Exchange Commission on October 1, 2020
Registration Statement on Form S-8 (No. 333-117173)
Registration Statement on Form S-8 (No. 333-140760)
Registration Statement on Form S-8 (No. 333-149253)
Registration Statement on Form S-8 (No. 333-157275)
Registration Statement on Form S-8 (No. 333-164892)
Registration Statement on Form S-8 (No. 333-172155)
Registration Statement on Form S-8 (No. 333-179760)
Registration Statement on Form S-8 (No. 333-190394)
Registration Statement on Form S-8 (No. 333-197582)
Registration Statement on Form S-8 (No. 333-206112)
Registration Statement on Form S-8 (No. 333-212991)
Registration Statement on Form S-8 (No. 333-219764)
Registration Statement on Form S-8 (No. 333-226759)
Registration Statement on Form S-8 (No. 333-233102)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-117173)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-140760)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-149253)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-157275)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-164892)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-172155)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-179760)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-190394)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-197582)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-206112)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-212991)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-219764)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-226759)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-233102)
Under
the Securities Act of 1933
Momenta Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 04-3561634 | |
(State or other jurisdiction of incorporation or
organization) |
(I.R.S. Employer Identification No.) |
301 Binney Street
Cambridge, Massachusetts 02142
(617) 491-9700
(Address, including zip code, and telephone number, including area code, of Registrants principal executive offices)
Momenta Pharmaceuticals, Inc. 2002 Stock Incentive Plan
Momenta Pharmaceuticals, Inc. 2004 Stock Incentive Plan
Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan
Momenta Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan
(Full title of the Plan)
Alejandra Carvajal Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge, Massachusetts 02142 (617) 491-9700 |
Copy to: Peter N. Handrinos Latham & Watkins LLP 200 Clarendon Street, 27th Floor Boston, Massachusetts 02116 (617) 948-6000 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company or emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment No. 1 relates to the following Registration Statements on Form S-8 (collectively, the Registration Statements) of Momenta Pharmaceuticals, Inc., a Delaware corporation (the Registrant or the Company), filed with the Securities and Exchange Commission (the SEC) and is being filed to deregister any and all securities that remain unsold or otherwise unissued under such Registration Statements:
|
Registration No. 333-117173 filed with the SEC on July 6, 2004, pertaining to the registration of 1,180,420 shares of common stock, par value $0.0001 per share, of the Company (Common Stock) for issuance under the Momenta Pharmaceuticals, Inc. 2002 Stock Incentive Plan, 3,948,785 shares of Common Stock for issuance under the Momenta Pharmaceuticals, Inc. 2004 Stock Incentive Plan (as amended, the 2004 Plan), and 524,652 shares of Common Stock for issuance under the Momenta Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan (as amended, the ESPP). |
|
Registration No. 333-140760 filed with the SEC on February 16, 2007, pertaining to the registration of an additional 1,802,053 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-149253 filed with the SEC on February 14, 2008, pertaining to the registration of an additional 1,823,491 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-157275 filed with the SEC on February 12, 2009, pertaining to the registration of an additional 1,846,116 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-164892 filed with the SEC on February 12, 2010, pertaining to the registration of an additional 1,974,303 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-172155 filed with the SEC on February 10, 2011, pertaining to the registration of an additional 1,974,393 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-179760 filed with the SEC on February 28, 2012, pertaining to the registration of an additional 1,974,393 shares of Common Stock for issuance under the 2004 Plan. |
|
Registration No. 333-190394 filed with the SEC on August 6, 2013, pertaining to the registration of 9,823,488 shares of Common Stock for issuance under the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan (as amended, the 2013 Plan). |
|
Registration No. 333-197582 filed with the SEC on July 23, 2014, pertaining to the registration of 500,000 shares of Common Stock for issuance under the ESPP and an additional 1,800,000 shares of Common Stock for issuance under the 2013 Plan. |
|
Registration No. 333-206112 filed with the SEC on August 5, 2015, pertaining to the registration of an additional 2,550,000 shares of Common Stock for issuance under the 2013 Plan. |
|
Registration No. 333-212991 filed with the SEC on August 8, 2016, pertaining to the registration of an additional 4,250,000 shares of Common Stock for issuance under the 2013 Plan. |
|
Registration No. 333- 219764 filed with the SEC on August 7, 2017, pertaining to the registration of an additional 1,400,000 shares of Common Stock for issuance under the ESPP and an additional 4,300,000 shares of Common Stock for issuance under the 2013 Plan. |
|
Registration No. 333- 226759 filed with the SEC on August 10, 2018, pertaining to the registration of an additional 1,000,000 shares of Common Stock for issuance under the 2013 Plan. |
|
Registration No. 333-233102 filed with the SEC on August 8, 2019, pertaining to the registration of an additional 4,000,000 shares of Common Stock for issuance under the 2013 Plan. |
On October 1, 2020, pursuant to an Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, a New Jersey corporation (Parent), Vigor Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), and the Company, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the Merger).
As a result of the Merger, the Registrant has terminated all offerings of the Registrants securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of such securities of the Registrant registered but not sold or otherwise issued under the Registration Statements, if any, as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of each Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these post-effective amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on October 1, 2020.
MOMENTA PHARMACEUTICALS, INC. |
||
By: |
/s/ Craig A. Wheeler |
|
|
||
Name: |
Craig A. Wheeler |
|
Title: |
President and Chief Executive Officer |
No other person is required to sign these post-effective amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.
1 Year Momenta Pharmaceuticals Chart |
1 Month Momenta Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions